Effects of Oral Administration of Fucoidan Extracted from Cladosiphon okamuranus on Tumor Growth and Survival Time in a Tumor-Bearing Mouse Model

Aso, Kazuo; Ishihara, Toshitsugu; Nakamoto, Hiroyuki; Amaha, Takao; Osaki, Tomohiro; Tsuka, Takeshi; Imagawa, Tomohiro; Minami, Saburo; Takashima, Osamu; Ifuku, Shinsuke; Morimoto, Minoru; Saimoto, Hiroyuki; Kawamoto, Hitoshi; Okamoto, Yoshiharu

doi:10.3390/md10102337

Cited by 66 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data suggest that the MyD88 signaling pathway may be downstream of SR-A and TLR-2 in this event. Moreover, recent studies have shown that the MyD88 signaling pathway is essential for SR-A ligand-induced antitumor effects in mouse NK cells (47) and for migration of human and mouse monocytes/macrophages (48). To address this hypothesis, we will characterize the downstream cascades of SR-A and TLR-2 signaling pathways in human BDCA1 ϩ mDCs stimulated by S. aureus, including the MyD88 signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

BDCA1-Positive Dendritic Cells (DCs) Represent a Unique Human Myeloid DC Subset That Induces Innate and Adaptive Immune Responses to Staphylococcus aureus Infection

Jin

Zhang

et al. 2014

Infect Immun

View full text Add to dashboard Cite

؉ mDCs, and these two receptors were both required for the recognition of S. aureus and the subsequent activation of BDCA1 ؉ mDCs. Finally, BDCA1 ؉ mDC-mediated immune responses against S. aureus were dependent on MyD88 signaling pathways. These results demonstrate that human BDCA1؉ mDCs represent a unique subset of mDCs that can respond to S. aureus to undergo maturation and activation and to induce Th1 and Tc1 immune responses.

show abstract

Section: Discussionmentioning

confidence: 99%

BDCA1-Positive Dendritic Cells (DCs) Represent a Unique Human Myeloid DC Subset That Induces Innate and Adaptive Immune Responses to Staphylococcus aureus Infection

Jin

Zhang

et al. 2014

Infect Immun

View full text Add to dashboard Cite

show abstract

“…Azuma et al suggested that, regardless of molecular weight (lower-molecular-weight fucoidan (LMWF: 6.6–40 kDa), intermediate-molecular-weight fucoidan (IMWF: 110–138 kDa), and high-molecular-weight fucoidan (HMWF: 300–330 kDa)), fucoidan-containing diet increases the survival time of mice [30]. Still, Matsubara et al argue that the pharmacological effects of fucoidan vary with molecular weight [31].…”

Section: Discussionmentioning

confidence: 99%

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib

Kim

Lü

et al. 2014

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2-targeting reagent lapatinib on cancer cells. Method. We selected six EGFR/ERBB2-amplified cancer cell lines (OE19, NCI-N87, OE33, ESO26, MKN7, and BT474) as an in vitro model and tested their sensitivity to DF alone and to DF in combination with the well-known EGFR/ERBB2-targeting reagent lapatinib. Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2-amplified cancer cells in vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI-N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.

show abstract

“…Furthermore, fucoidan has been shown to display immune-stimulating effects on dendritic (DC) cells [460][461][462][463] and natural killer (NK) cells [412,464]. Thus, fucoidan can enhance anticancer immunity through immune cell activation and influx and stimulation of the production of anticancer cytokines [10,421].…”

Section: Anticancer Activity Of Fucoidanmentioning

confidence: 99%

Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines

Abudabbus

Badmus

Shalaweh

et al. 2017

CPB

View full text Add to dashboard Cite

Fucoidan is an effective antitumor agent, either alone or in combination with cisplatin, doxorubicin and taxol in MCF-7 breast cancer cells. Drug combinations that discriminate between cancerous and non-cancerous cells afford a plausible and viable strategy of attaining therapeutic efficacy and avoiding possible toxicity and side effects. These findings suggest that fucoidan is a promising candidate for cancer combination therapies.

show abstract

Effects of Oral Administration of Fucoidan Extracted from Cladosiphon okamuranus on Tumor Growth and Survival Time in a Tumor-Bearing Mouse Model

Cited by 66 publications

References 31 publications

BDCA1-Positive Dendritic Cells (DCs) Represent a Unique Human Myeloid DC Subset That Induces Innate and Adaptive Immune Responses to Staphylococcus aureus Infection

BDCA1-Positive Dendritic Cells (DCs) Represent a Unique Human Myeloid DC Subset That Induces Innate and Adaptive Immune Responses to Staphylococcus aureus Infection

Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib

Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines

Contact Info

Product

Resources

About